ProscaVax is a therapeutic cancer vaccine for prostate cancer patients.
The vaccine incorporates scientifically proven and clinically validated treatments for cancer.
Patented technology developed and or acquired by OncBioMune is used in the production of this prostate cancer treatment.
The intellectual property consists of multiple technologies combined with laboratory and clinical procedures that provide new insight into the treatment of cancer.
Clinical Trial NCT02058680: Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone-Independent Patients (PSA)
This study is investigating the safety and efficacy of a vaccine directed against prostate tumor cells. The researchers are interested in evaluating the safety and tolerability of the vaccine, and the effects of the vaccine on survivability, time to measurable disease, prostate-specific antigen (PSA) level in the blood, and the immune response to the vaccine.
Eligible patients include those with recurrent prostate cancer as shown by elevated levels of PSA, although there is no evidence of tumors that are measurable by imaging studies. In addition, to be eligible patients must have prostate cancer that either has not been treated by hormonal therapy or is not responsive to hormonal therapy.
Data from a phase 1/2 clinical trial of the therapeutic prostate cancer vaccine:
- 12 Patients with prostate cancer confirmed by biopsy and with an elevated PSA received the vaccine.
- All patients received their initial course of six vaccinations containing prostate-specific antigen and biological adjuvant.
- Serum PSA concentrations were determined before initiating vaccination and 3-4 weeks after the 6th vaccination.
- Two-thirds of the prostate cancer patients’ PSAs decreased after vaccination.
- During the trial, the prostate cancer patients received no other concurrent therapy (surgery, hormone, radiation, radioactive seeds, chemotherapy), and have additionally received three further vaccinations alternated with low dose IL-2 for the 6 months following the initial vaccinations.